上半年基金成绩单出炉：“吃药”行情卷土重来，医药霸榜TOP10
3 6 Ke·2025-07-01 10:24

Group 1: Market Overview - In the first half of 2025, global capital markets experienced significant fluctuations, with different markets showing various highlights. The US stock market saw the Dow Jones increase by 3.64%, the Nasdaq 100 by 7.93%, and the S&P 500 by 5.5% [1] - The Hong Kong stock market outperformed, with the Hang Seng Index, Hang Seng Tech Index, and Hang Seng China Enterprises Index rising by 20%, 18.68%, and 19.05% respectively, indicating a strong capital inflow into Hong Kong stocks [1] - A-shares showed a structural market trend, with small-cap stocks outperforming larger indices, as evidenced by the Shanghai Stock Exchange 50 Index rising by only 1.01% while the CSI 2000 Index increased by 15.24% [1] Group 2: Fund Performance - As of June 30, 2025, there were 22,090 open-end funds (excluding money market and QDII funds) in the domestic market, with 86.26% of them generating positive returns in the first half of the year [2] - Among QDII funds, 87.15% achieved positive returns, with 13.15% of these funds yielding returns of 20% or more [2] - A total of 988 open-end funds outperformed the Hang Seng Index, representing 4.34% of all non-money market funds, indicating a concentration of high-quality products [2] Group 3: Top Performing Funds - The top 20 open-end funds in terms of performance for the first half of 2025 had returns ranging from 82.45% to 56.70%, significantly outperforming major indices [3] - The majority of these top-performing funds were heavily invested in the healthcare sector, with 11 out of the 20 funds focusing on the pharmaceutical and health industries [4][5] - In the QDII category, the top 10 funds had returns between 86% and 46.71%, with all funds heavily weighted in pharmaceutical stocks [9][10] Group 4: Sector Analysis - The healthcare sector, particularly innovative pharmaceuticals, showed remarkable performance, with the A-share innovative drug concept rising by 26.1% and the Hang Seng Biotechnology Index increasing by 50.65% [13] - The strong performance of the pharmaceutical sector has led to a significant recovery for funds that were previously underperforming in this category, marking a notable turnaround in the market [13]